Research Topic · Peer-Reviewed

Cyclophosphamide

Cyclophosphamide is a nitrogen mustard alkylating agent used as a chemotherapeutic and immunosuppressive drug. It is a prodrug, requiring hepatic activation by cytochrome P450 enzymes to form active metabolites, principally phosphoramide mustard, which cross-link DNA strands and thereby block replication and trigger…

Curated from this journal's research 📚 8 peer-reviewed articles cited Cited 24× across the literature 🗓 Reviewed June 2026

Overview

Cyclophosphamide is a nitrogen mustard alkylating agent used as a chemotherapeutic and immunosuppressive drug. It is a prodrug, requiring hepatic activation by cytochrome P450 enzymes to form active metabolites, principally phosphoramide mustard, which cross-link DNA strands and thereby block replication and trigger death of rapidly dividing cells. Through this mechanism it is employed in the treatment of haematological malignancies such as leukaemias and lymphomas and several solid tumours, and at lower doses to suppress aberrant immune activity in autoimmune and inflammatory disorders, including the conditioning regimens used before haematopoietic stem cell transplantation. Because its cytotoxic action is not confined to tumour cells, cyclophosphamide produces dose-limiting toxicities affecting other proliferating tissues, including myelosuppression, urothelial injury, and impaired gametogenesis; experimental work has examined its capacity to inhibit spermatogenesis and induce oxidative stress, together with protective strategies against these effects. It is frequently combined with other agents in multidrug protocols to enhance efficacy and is relevant to the management of transplant-associated lymphoproliferative disorders and stem-cell mobilisation contexts. Related research addresses its role in oncology and transplantation, its reproductive and oxidative toxicity, and complementary measures intended to mitigate organ damage while preserving the drug's antineoplastic and immunomodulatory benefits.

Research published in this journal

8 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 8 articles above have been cited 24 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Cyclophosphamide, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Advances in Leukemia.

Journal editorial board
Hang Su · United States Ewelina Grywalska · Poland Antonio Ruggiero · Italy

This page summarises published research for orientation; it is not medical or professional advice.